Aktis Oncology, Inc.(AKTS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AKTS Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Aktis Oncology, Inc. (AKTS), a Healthcare sector company. AKTS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Aktis Oncology, Inc. reports quarterly revenue of $3.4M, net income of $-24.1M, free cash flow of $-21.8M. Top institutional holders of AKTS by reported 13-F value include MPM BioImpact, EcoR1 Capital, Blue Owl Capital, based on the most recent SEC filings. AKTS trades on the Nasdaq exchange and files with the SEC under CIK 2035832. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aktis Oncology, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$3.4M
Net Income
Q2 2026
$-24.1M
Free Cash Flow
Q2 2026
$-21.8M
ROIC
Q2 2026
-23.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProTotal Assets
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Total Assets | $264.9M | — |
Get alerted when AKTS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Aktis Oncology, Inc. including:
Top Institutional Holders of AKTS
MPM BioImpact LLC
$155.9M4,835,872 shEcoR1 Capital, LLC
$155.5M4,824,469 shBlue Owl Capital Holdings LP
$99.0M3,070,219 shBlackRock, Inc.
$73.4M2,278,358 shT. Rowe Price Investment Management, Inc.
$66.1M2,051,447 shWELLINGTON MANAGEMENT GROUP LLP
$63.4M1,966,244 shRTW INVESTMENTS, LP
$51.3M1,592,043 shRA CAPITAL MANAGEMENT, L.P.
$42.4M1,314,405 shJupiter Topco LLC
$42.4M1,314,267 shBAKER BROS. ADVISORS LP
$32.1M996,351 sh
| Fund | Value | Shares |
|---|---|---|
| MPM BioImpact LLC | $155.9M | 4,835,872 |
| EcoR1 Capital, LLC | $155.5M | 4,824,469 |
| Blue Owl Capital Holdings LP | $99.0M | 3,070,219 |
| BlackRock, Inc. | $73.4M | 2,278,358 |
| T. Rowe Price Investment Management, Inc. | $66.1M | 2,051,447 |
| WELLINGTON MANAGEMENT GROUP LLP | $63.4M | 1,966,244 |
| RTW INVESTMENTS, LP | $51.3M | 1,592,043 |
| RA CAPITAL MANAGEMENT, L.P. | $42.4M | 1,314,405 |
| Jupiter Topco LLC | $42.4M | 1,314,267 |
| BAKER BROS. ADVISORS LP | $32.1M | 996,351 |
More Healthcare Companies
View all Healthcare →Put AKTS on your watchlist
Track score changes the day Aktis Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AKTS a good stock to buy?
13F Pro's AI-powered analysis of Aktis Oncology, Inc. (AKTS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AKTS are available on the AKTS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AKTS is classified as a small company.
Which hedge funds own AKTS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AKTS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aktis Oncology, Inc.'s investment landscape.